Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions

Blood

Volumn 122, Issue 7, 2013, Pages 1174-1181

  Mathiesen, Line ^a   Nielsen, Leif K ^b   Andersen, Jan Terje ^c,d   Grevys, Algirdas ^c,d   Sandlie, Inger ^c,d   Michaelsen, Terje E ^c,e   Hedegaard, Morten ^b   Knudsen, Lisbeth E ^a   Dziegiel, Morten Hanefeld ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIMALARIAL AGENT; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G3 ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT IMMUNOGLOBULIN G3 ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CASE REPORT; CELL TRANSPORT; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; EX VIVO STUDY; FETUS CIRCULATION; GENE DELETION; HINGE REGION; HUMAN; MATERNOFETAL TRANSPLACENTAL TRANSPORT; PLACENTA PERFUSION; PLACENTAL TRANSFER; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BINDING; TRANSCYTOSIS; TROPHOBLAST; CHORIOCARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETOMATERNAL TRANSFUSION; FETUS; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; NEWBORN; PATHOLOGY; PLACENTA; PREGNANCY; TRANSPORT AT THE CELLULAR LEVEL; UTERUS CANCER;

ANTIBODIES; BINDING SITES; BIOLOGICAL TRANSPORT; CHORIOCARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; RECEPTORS, FC; RECOMBINANT PROTEINS; UTERINE NEOPLASMS;

EID: 84887130797     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-473843     Document Type: Article

References (47)

1. Firan M, Bawdon R, Radu C, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol. 2001;13(8):993-1002.
2. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol. 1996;157(8):3317-3322.
3. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9):715-725.
4. Story CM, Mikulska JE, Simister NE. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med. 1994;180(6):2377-2381.
5. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrowderived cells functions to protect serum IgG from catabolism. J Immunol. 2007;179(7):4580-4588.
6. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol. 1999;29(9):2819-2825.
7. Kobayashi K, Qiao SW, Yoshida M, Baker K, Lencer WI, Blumberg RS. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology. 2009;137(5):1746-1756.
8. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A. 2009;106(8):2788-2793.
9. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol. 1997;158(5):2211-2217.
10. Stapleton NM, Andersen JT, Stemerding AM, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2: 599.
11. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833-839.
12. Nordvall M, Dziegiel M, Hegaard HK, et al. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion. 2009;49(10): 2070-2075.
13. Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev. 2011;(5):CD004226.
14. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008;112(1):164-176.
15. Chen P, Li C, Lang S, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood. 2010;116(18):3660-3668.
16. Klein M, Haeffner-Cavaillon N, Isenman DE, et al. Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region. Proc Natl Acad Sci U S A. 1981;78(1): 524-528.
17. Guddat LW, Herron JN, Edmundson AB. Threedimensional structure of a human immunoglobulin with a hinge deletion. Proc Natl Acad Sci U S A. 1993;90(9):4271-4275.
18. Michaelsen TE, Brekke OH, Aase A, Sandin RH, Bremnes B, Sandlie I. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge. Proc Natl Acad Sci U S A. 1994;91(20):9243-9247.
19. Nielsen LK, Green TH, Sandlie I, Michaelsen TE, Dziegiel MH. In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn. Transfusion. 2008;48(1):12-19.
20. Ellinger I, Rothe A, Grill M, Fuchs R. Apical to basolateral transcytosis and apical recycling of immunoglobulin G in trophoblast-derived BeWo cells: effects of low temperature, nocodazole, and cytochalasin D. Exp Cell Res. 2001;269(2): 322-331.
21. Mathiesen L, Mose T, Mørck TJ, et al. Quality assessment of a placental perfusion protocol. Reprod Toxicol. 2010;30(1):138-146.
22. Nielsen LK, Norderhaug L, Sandlie I, Dziegiel MH. In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells. APMIS. 2006;114(5):345-351.
23. Lundquist R, Nielsen LK, Jafarshad A, et al. Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect Immun. 2006;74(6): 3222-3231.
24. Andersen JT, Foss S, Kenanova VE, et al. Anticarcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem. 2012; 287(27):22927-22937.
25. Berntzen G, Lunde E, Flobakk M, Andersen JT, Lauvrak V, Sandlie I. Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J Immunol Methods. 2005; 298(1-2):93-104.
26. Andersen JT, Justesen S, Fleckenstein B, et al. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS J. 2008; 275(16):4097-4110.
27. Bode CJ, Jin H, Rytting E, Silverstein PS, Young AM, Audus KL. In vitro models for studying trophoblast transcellular transport. Methods Mol Med. 2006;122:225-239.
28. Poulsen MS, Rytting E, Mose T, Knudsen LE. Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. Toxicol In Vitro. 2009;23(7): 1380-1386.
29. Myllynen P, Mathiesen L, Weimer M, et al. Preliminary interlaboratory comparison of the ex vivo dual human placental perfusion system. Reprod Toxicol. 2010;30(1):94-102.
30. Kumpel BM. A simple non-isotopic method for the quantitation of red cell-bound immunoglobulin. Vox Sang. 1990;59(1):34-38.
31. Nielsen LK, Green TH, Norderhaug L, Sandlie I, Dziegiel MH. Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D. Transfusion. 2007; 47(2):306-315.
32. Deisenhofer J, Jones TA, Huber R, Sjödahl J, Sjöquist J. Crystallization, crystal structure analysis and atomic model of the complex formed by a human Fc fragment and fragment B of protein A from Staphylococcus aureus. Hoppe Seylers Z Physiol Chem. 1978;359(8):975-985.
33. Ellinger I, Schwab M, Stefanescu A, Hunziker W, Fuchs R. IgG transport across trophoblastderived BeWo cells: a model system to study IgG transport in the placenta. Eur J Immunol. 1999; 29(3):733-744.
34. Hashira S, Okitsu-Negishi S, Yoshino K. Placental transfer of IgG subclasses in a Japanese population. Pediatr Int. 2000;42(4):337-342.
35. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372(6504): 379-383.
36. Jefferis R, Lund J. Interaction sites on human IgGFc for FcgammaR: current models. Immunol Lett. 2002;82(1-2):57-65.
37. Lyden TW, Robinson JM, Tridandapani S, et al. The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fc gamma RIIb2. J Immunol. 2001;166(6):3882-3889.
38. Gafencu A, Heltianu C, Burlacu A, Hunziker W, Simionescu M. Investigation of IgG receptors expressed on the surface of human placental endothelial cells. Placenta. 2003;24(6):664-676.
39. Kim J, Mohanty S, Ganesan LP, et al. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J Immunol. 2009;182(5): 2583-2589.
40. Mohanty S, Kim J, Ganesan LP, et al. IgG is transported across the mouse yolk sac independently of FcgammaRIIb. J Reprod Immunol. 2010;84(2):133-144.
41. He W, Ladinsky MS, Huey-Tubman KE, Jensen GJ, McIntosh JR, Björkman PJ. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature. 2008;455(7212): 542-546.
42. Prabhat P, Gan Z, Chao J, et al. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci U S A. 2007;104(14):5889-5894.
43. Armour KL, Parry-Jones DR, Beharry N, et al. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood. 2006;107(7): 2619-2626.
44. Armstrong-Fisher SS, Sims AM, Falconer D, et al. In vitro materno-fetal transfer of native and Fcmutated recombinant RhD antibodies [abstract]. Vox Sang. 2004;87(suppl s3):37.
45. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A. 2006;103(49):18709-18714.
46. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Nørgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;1(8493):1287-1293.
47. Joutsi-Korhonen L, Preston S, Smethurst PA, et al. The effect of recombinant IgG antibodies against the leucine-33 form of the platelet beta3 integrin (HPA-1a) on platelet function. Thromb Haemost. 2004;91(4):743-754.